Andrew Loring Schilb
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$1.8MFederal grants as PI5 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
5 awards · $1.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 7, 2026 | NIH | SBIR Phase I In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease | $208K | JANUSQ, LLC |
| Sep 19, 2025 | NIH | SBIR Phase I Pharmacokinetics and in vivo efficacy of DA1 macrocyclic peptides in a murine model of Alzheimer's disease | $577K | JANUSQ, LLC |
| Sep 12, 2025 | NIH | SBIR Phase I In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease | $491K | JANUSQ, LLC |
| Sep 16, 2022 | NIH | SBIR Phase I Pharmacokinetic and pharmacodynamic assessment of peptide-based therapy DA1 for the treatment of Alzheimer's disease | $260K | JANUSQ, LLC |
| Dec 15, 2020 | NIH | SBIR Phase I Pharmacokinetic Assessment of Peptide-Based Therapy HV-3 for the Treatment of Huntington's Disease | $241K | JANUSQ, LLC |
Peer ranks
Federal funding#1,188
Awards as PI#417
Patents#273
Companies
- JANUSQ, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.